Novartis Gets Priority Review for Kidney Disease Treatment
By Ben Glickman
Novartis said it received priority review for Fabhalta as a potential treatment for IgA nephropathy, a rare kidney disease.
The pharmaceutical company said Monday that its submission to the U.S. Food and Drug Administration for potential accelerated approval of its treatment had been accepted. The company's IgA nephropathy treatment has received priority review, the company said, which means regulators are aiming to act on the application within six months.
The company's treatment Fabhalta is being evaluated in a Phase 3 trial. An interim analysis found a clinically meaningful and statistically significant reduction in proteinuria, a surrogate marker which correlates to progression to kidney failure.
Accelerated approval from the FDA allows for drugs that treat a serious condition with an unmet medical need to be approved using surrogate endpoints, or an indirect marker believed to predict a clinical effect.
Fabhalta received FDA approval in December 2023 to treat adults with the rare blood disorder paroxysmal nocturnal hemoglobinuria.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
April 15, 2024 14:40 ET (18:40 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks